J&J earnings set ‘negative tone’; Shkreli vs. the FTC
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.